Developers: | Zap Surgical Systems |
Branches: | Pharmaceuticals, Medicine, Healthcare |
2024: Entering the Russian market
In June 2024, R-Pharm Holding brought to the Russian market the ZAP-X radiosurgical platform, designed for stereotactic radiosurgery without the use of cobalt. This innovative device is developed by the American company Zap Surgical Systems and is based on the use of the powerful medical linear accelerator IMG Altair, which concentrates radiosurgical beams on tumors from various angles, minimizing the impact on healthy tissues.
Roszdravnadzor issued a registration certificate for ZAP-X on June 7, 2024, which opened the way for its official use in Russia. The ZAP-X platform is equipped with a self-screening system, which allows you to install it both in specialized clinics and in ordinary medical offices, without requiring complex preparation of the radiation protection system.
ZAP-X represents a significant breakthrough in the treatment of brain tumors and other head and neck diseases. The system directs radiosurgical beams at thousands of angles, focusing exclusively on the tumor and ensuring maximum accuracy and safety of treatment. One of the key advantages of the platform is the absence of the need to use cobalt, which makes it safer and more accessible to patients.
The creator of Zap Surgical Systems is John Adler, one of the inventors of the Cyberknife system. Despite the success of Cyberknife, its high cost limited distribution. In contrast, ZAP-X is designed for wider use due to the reduced cost of maintenance and treatment, which makes it available to more patients.
The ZAP-X platform began to be used en masse in 2022 and has already proven itself internationally. In November 2022, the device was installed in Poland, in April 2023 - in France, in June - in South Korea, and also received approval for use in China. Since the spring of 2023, more than 1,000 patients have been treated with ZAP-X.